$421,000 cancer drug Kymriah becomes eligible for reimbursement

Korea Biomedical Review

14 January 2022 - Novartis’ breakthrough cancer treatment Kymriah (ingredient: tisagenlecleucel), which costs over 500 million won (US$421,000), has become eligible for reimbursement, the health insurance review agency said.

In October, the Cancer Review Committee set two indications as the criteria for Kymriah reimbursement -- diffuse large B-cell lymphoma in adults and B-cell acute lymphoblastic leukaemia in children and young adults. Then, the treatment passed the review of the Drug Reimbursement Evaluation Committee this year.

Read Korea Biomedical Review article 

Michael Wonder

Posted by:

Michael Wonder